Provention Bio (PRVB) Announces Trading Halted Today for FDA Advisory Committee Meeting on Teplizumab

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that Nasdaq has halted trading of the Company's common stock.

The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee is meeting today to discuss the Biologics License Application (BLA) for teplizumab for the delay of clinical type 1 diabetes (T1D) in at-risk individuals. The Advisory Committee meeting is scheduled to start at 9:00 a.m. ET. The meeting can be accessed at: https://investors.proventionbio.com/events.

You May Also Be Interested In

• Coherus and Zumutor to run Phase 1 trial combining ZM008 and Loqtorzi
• EU approves AbbVie's Skyrizi for children with plaque psoriasis
• Zeta Surgical begins TMS navigation treatments at Hope Therapeutics clinics